Referenslista
Referenslista till forskningsartikel om SSRI, Mind nr. 2, år 2020
1. Ferguson JM. SSRI antidepressant medications: adverse effects and tolerability. Primary care companion to the Journal of clinical psychiatry 2001;3(1):22.
2. Trivedi MH, Rush AJ, Wisniewski SR, et al. Evaluation of outcomes with citalopram for depression using measurement-based care in STAR* D: implications for clinical practice. American journal of Psychiatry 2006;163(1):28-40.
3. Cipriani A, Furukawa TA, Salanti G, et al. Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: a systematic review and network meta-analysis. Focus 2018;16(4):420-29.
4. Cipriani A, Zhou X, Del Giovane C, et al. Comparative efficacy and tolerability of antidepressants for major depressive disorder in children and adolescents: a network meta-analysis. The Lancet 2016;388(10047):881-90.
5. Locher C, Koechlin H, Zion SR, et al. Efficacy and safety of selective serotonin reuptake inhibitors, serotonin-norepinephrine reuptake inhibitors, and placebo for common psychiatric disorders among children and adolescents: a systematic review and meta-analysis. JAMA psychiatry 2017;74(10):1011-20.
6. Insel TR, Wang PS. The STAR* D trial: revealing the need for better treatments. Psychiatric services 2009;60(11):1466-67.
7. Fried EI, Nesse RM. Depression sum-scores don’t add up: why analyzing specific depression symptoms is essential. BMC medicine 2015;13(1):72.
8. Friedman RA. Antidepressants’ black-box warning—10 years later. New England Journal of Medicine 2014;371(18):1666-68.
9. Gibbons RD, Brown CH, Hur K, et al. Early evidence on the effects of regulators’ suicidality warnings on SSRI prescriptions and suicide in children and adolescents. American Journal of Psychiatry 2007;164(9):1356-63.
10. Sharma T, Guski LS, Freund N, et al. Suicidality and aggression during antidepressant treatment: systematic review and meta-analyses based on clinical study reports. Bmj 2016;352:i65.
11. Dragioti E, Solmi M, Favaro A, et al. Association of Antidepressant Use With Adverse Health Outcomes: A Systematic Umbrella Review. JAMA Psychiatry 2019;76(12):1241-55. doi: 10.1001/jamapsychiatry.2019.
12. Molero Y, Lichtenstein P, Zetterqvist J, et al. Selective serotonin reuptake inhibitors and violent crime: a cohort study. PLoS medicine 2015;12(9):e1001875.
13. Hiemke C, Härtter S. Pharmacokinetics of selective serotonin reuptake inhibitors. Pharmacology & therapeutics 2000;85(1):11-28.
14. Probst-Schendzielorz K, Viviani R, Stingl JC. Effect of Cytochrome P450 polymorphism on the action and metabolism of selective serotonin reuptake inhibitors. Expert opinion on drug metabolism & toxicology 2015;11(8):1219-32.
15. Tanaka E, Hisawa S. Clinically significant pharmacokinetic drug interactions with psychoactive drugs: antidepressants and antipsychotics and the cytochrome P450 system. Journal of clinical pharmacy and therapeutics 1999;24(1):7-16.
16. Abbing-Karahagopian V, Huerta C, Souverein PC, et al. Antidepressant prescribing in five European countries: application of common definitions to assess the prevalence, clinical observations, and methodological implications. European journal of clinical pharmacology 2014;70(7):849-57. doi: 10.1007/s00228-014-1676-z
17. Pratt LA, Brody DJ, Gu Q. Antidepressant Use among Persons Aged 12 and Over: United States, 2011-2014. NCHS Data Brief. Number 283. National Center for Health Statistics 2017
18. Läkemedelsverket. Depression, ångestsyndrom och tvångssyndrom hos barn och vuxna – behandlingsrekommendation: Information från Läkemedelsverket. 2016;27(6):26–59.
19. Davies J, Read J. A systematic review into the incidence, severity and duration of antidepressant withdrawal effects: Are guidelines evidence-based? Addictive behaviors 2018 doi: https://doi.org/10.1016/j.
20. Iacobucci G. NICE updates antidepressant guidelines to reflect severity and length of withdrawal symptoms: British Medical Journal Publishing Group, 2019.